The size of the Biosurgery market in the Europe region was worth USD 5.18 billion in 2019 and estimated to be growing at a CAGR of 8.43%, to reach USD 7.77 billion by 2024 during the forecast period 2019 - 2024.
BioSurgery is an area dedicated to providing aid in surgery by focusing on an array of technologies to minimize the intra- and post-operative complications. Solutions commonly used in biosurgery comprise innovative, biologically based products for surgical conditions that are often difficult or expensive to manage otherwise.
Biosurgery uses biomaterial, therapeutic, and sophisticated device technologies to improve the health of patients in the orthopedic and post-surgery care departments. Most biosurgery products work by facilitating homeostasis and tissue healing in surgery. An example of this is fibrin sealant which consists of human fibrinogen and thrombin and helps replicate the tissue healing process by facilitating clotting of blood and thereby stopping the bleeding.
The major driver of the Europe Bio Surgery market is the strong focus on research development, which in turn leads to the launch of various new products and various other technological advancements in the field. This along with the increasing number of surgeries due to changing lifestyles and increasing consumer awareness serve as boosters for the market growth.
The major factor restraining the Bio Surgery market in Europe is the non-acceptance of certain products such as human tissue, which is essential for regenerative purposes, due to ethical concerns in certain parts of the region. This along with the high costs and the stringent government regulations act as restraints for the market.
This research report on the Europe BioSurgery Market has been segmented and sub-segmented into the following categories.
Promising companies leading the Europe Biosurgery Market profiled in this report are Baxter International, C.R. Bard, Johnson & Johnson, Covidien PLC, Getinge Group, B. Braun Melsungen AG, Cryolife Inc., Stryker Corporation, Hemostasis LLC., and Sanofi Group.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Type
5.1.1 Introduction
5.1.2 Sealants
5.1.2.1 Natural
5.1.2.2 Synthetic and Semi-Synthetic
5.1.3 Haemostatic Agents
5.1.4 Adhesion Barriers
5.1.4.1 Synthetic
5.1.4.2 Natural
5.1.5 Soft Tissue Attachments
5.1.5.1 Synthetic Meshes
5.1.5.2 Biological Meshes
5.1.7 Bone Graft Substitutes
5.1.7.1 Bone Allografts
5.1.7.2 Demineralized Bone Matrix
5.1.7.3 Bone Morphogenetic Proteins
5.1.7.4 Synthetic Bone Grafts
5.1.8 Staple Line Reinforcement Agents
5.1.9 Y-o-Y Growth Analysis, By Type
5.1.10 Market Attractiveness Analysis, By Type
5.1.11 Market Share Analysis, By Type
5.2 Application
5.2.1 Introduction
5.2.2 Orthopaedic
5.2.3 General
5.2.4 Neurological
5.2.5 Cardiovascular
5.2.6 Reconstructive
5.2.7 Gynaecological
5.2.8 Urological
5.2.9 Thoracic
5.2.10 Y-o-Y Growth Analysis, By Application
5.2.11 Market Attractiveness Analysis, By Application
5.2.12 Market Share Analysis, By Application
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Application
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Baxter International
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 C.R. Bard
8.3 Covidien PLC
8.4 Johnson & Johnson
8.5 Sanofi Group
8.6 Atrium Medical Corporation
8.7 B.Braun Melsungen AG
8.8 Cryolife Inc.
8.9 Stryker Corporation
8.10 Haemostasis LLC
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
Appendix
Related Reports
